Literature DB >> 24670323

Spectrum of HIV antibodies in vaccine and disease.

Georgia D Tomaras1, David C Montefiori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24670323      PMCID： PMC4321716          DOI： 10.1097/COH.0000000000000060

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN： 1746-630X            Impact factor:   4.283


× No keyword cloud information.
  12 in total

1.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

2.  Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Authors:  Pinghuang Liu; Nicole L Yates; Xiaoying Shen; Mattia Bonsignori; M Anthony Moody; Hua-Xin Liao; Youyi Fong; S Munir Alam; R Glenn Overman; Thomas Denny; Guido Ferrari; Christina Ochsenbauer; John C Kappes; Victoria R Polonis; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; David C Montefiori; Peter Gilbert; Nelson L Michael; Jerome H Kim; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

3.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

4.  The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

Authors:  Mark S de Souza; Silvia Ratto-Kim; Weerawan Chuenarom; Alexandra Schuetz; Somsak Chantakulkij; Bessara Nuntapinit; Anais Valencia-Micolta; Doris Thelian; Sorachai Nitayaphan; Punnee Pitisuttithum; Robert M Paris; Jaranit Kaewkungwal; Nelson L Michael; Supachai Rerks-Ngarm; Bonnie Mathieson; Mary Marovich; Jeffrey R Currier; Jerome H Kim
Journal:  J Immunol       Date:  2012-04-23       Impact factor: 5.422

5.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

6.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

7.  Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.

Authors:  Supachai Rerks-Ngarm; Robert M Paris; Supamit Chunsutthiwat; Nakorn Premsri; Chawetsan Namwat; Chureeratana Bowonwatanuwong; Shuying S Li; Jaranit Kaewkungkal; Rapee Trichavaroj; Nampueng Churikanont; Mark S de Souza; Charla Andrews; Donald Francis; Elizabeth Adams; Jorge Flores; Sanjay Gurunathan; Jim Tartaglia; Robert J O'Connell; Chirapa Eamsila; Sorachai Nitayaphan; Viseth Ngauy; Prasert Thongcharoen; Prayura Kunasol; Nelson L Michael; Merlin L Robb; Peter B Gilbert; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-07-26       Impact factor: 5.226

8.  Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.

Authors:  Georgia D Tomaras; Guido Ferrari; Xiaoying Shen; S Munir Alam; Hua-Xin Liao; Justin Pollara; Mattia Bonsignori; M Anthony Moody; Youyi Fong; Xi Chen; Brigid Poling; Cindo O Nicholson; Ruijun Zhang; Xiaozhi Lu; Robert Parks; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Peter B Gilbert; Jerome H Kim; Nelson L Michael; David C Montefiori; Barton F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-09       Impact factor: 11.205

9.  Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Authors:  David C Montefiori; Chitraporn Karnasuta; Ying Huang; Hasan Ahmed; Peter Gilbert; Mark S de Souza; Robert McLinden; Sodsai Tovanabutra; Agnes Laurence-Chenine; Eric Sanders-Buell; M Anthony Moody; Mattia Bonsignori; Christina Ochsenbauer; John Kappes; Haili Tang; Kelli Greene; Hongmei Gao; Celia C LaBranche; Charla Andrews; Victoria R Polonis; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Steve G Self; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Jim Tartaglia; Merlin L Robb; Barton F Haynes; Nelson L Michael; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-05-25       Impact factor: 5.226

10.  Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.

Authors:  Susan Zolla-Pazner; Allan deCamp; Peter B Gilbert; Constance Williams; Nicole L Yates; William T Williams; Robert Howington; Youyi Fong; Daryl E Morris; Kelly A Soderberg; Carmela Irene; Charles Reichman; Abraham Pinter; Robert Parks; Punnee Pitisuttithum; Jaranit Kaewkungwal; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Charla Andrews; Robert J O'Connell; Zhi-yong Yang; Gary J Nabel; Jerome H Kim; Nelson L Michael; David C Montefiori; Hua-Xin Liao; Barton F Haynes; Georgia D Tomaras
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240
View more
  1 in total

1.  Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.

Authors:  Timothy Cardozo; Shixia Wang; Xunqing Jiang; Xiang-Peng Kong; Catarina Hioe; Chavdar Krachmarov
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.